Market Research Report
Global Psoriatic Arthritis Therapeutics Market - 2019-2026
|Published by||DataM Intelligence||Product code||834581|
|Published||Content info||130-180 Pages
Delivery time: 1-2 business days
|Global Psoriatic Arthritis Therapeutics Market - 2019-2026|
|Published: May 1, 2019||Content info: 130-180 Pages||
Psoriatic arthritis is a chronic autoimmune inflammatory disease that is characterized by inflammation, swelling, and stiffness in joints and surrounding ligaments and tendons of the body and itchy, scaly red patches on the skin. The common symptoms of psoriatic arthritis include swollen fingers, toes, and tender joints, stiffness, lower back pain, and pitted nails. Psoriatic arthritis is a non-curable disease and treatments are aimed at relieving the symptoms of the condition. Various over-the-counter prescription drugs are available and several more are in different stages of clinical trials in order to treat the symptoms of psoriatic arthritis. Psoriatic arthritis is believed to be hereditary in nature.
Large patient population is suffering from moderate to severe psoriatic arthritis with unmet medical needs, and the number is increasing across the globe. According to the World Health Organization (WHO), in 2018, more than 150 million people around the world were affected by psoriasis, and 30% of the psoriasis population tend to develop psoriatic arthritis. This disease falls in the progressive category of diseases that may get worse over time. If left untreated, psoriatic arthritis may lead to joint damage permanently due to the degeneration of the cartilages present in the joints. Psoriatic arthritis is more likely to occur in adults. Men and women are equally affected by it and it occurs between the ages of 30 to 50 years. Many times, psoriatic arthritis is misdiagnosed as osteoarthritis, rheumatoid arthritis, or gout. People with psoriatic arthritis are more likely to suffer from high blood pressure, heart disease, high cholesterol, and diabetes. The disease can be ruled out with blood test and other imaging techniques like Magnetic resonance imaging, ultrasound scan and x-ray of the back, hand feet. Treatment of psoriatic arthritis involves the use of biologic drugs, enzyme inhibitors, disease-modifying rheumatoid arthritis drugs, and nonsteroidal anti-inflammatory drugs. Several drugs are into clinical testing which depicts the possibility of discovering new molecules with maximum activity and minimum side effects.
The global psoriatic arthritis therapeutics market was worth $XX million in 2018 and is forecasted to reach $XX million by 2026, at a CAGR of XX% during the forecast period.
The market is driven by an increase in the prevalence of psoriatic arthritis, new product development, rise in adoption of biologics for the treatment of moderate to severe psoriatic arthritis and large patient population with unmet medical needs across the globe.
Prescribed drugs for psoriatic arthritis include immune-suppressing drugs, non-steroidal drugs, and various biologics. Biologics majorly works by stopping the inflammatory condition. Tumor necrosis factor (TNF) and interleukin (IL) inhibitors are mostly used to treat psoriatic arthritis. The current research trend depicts that more emphasis is given for biologics. Biosimilar TNF alpha inhibitors present a more significant challenge to broader uptake of Novartis' IL-17 inhibitor, Cosentyx, and Eli Lilly's Taltz. The companies are developing new biologics based on IL-17 inhibitors.
The high cost of the drugs, generic erosion and treatment and lack of standardization tools for diagnosis and treatment are going to restrain the market in the forecast period.
The global psoriatic arthritis therapeutics market can be segmented by drug class as Nonsteroidal anti-inflammatory drugs (NSAIDs), Disease-modifying antirheumatic drugs (DMARD) and biologic drugs. DMARDs is further segmented as antimalarials and corticosteroids; and biologic drug are further segmented as TNF-alpha inhibitors, IL-inhibitors and T cells inhibitors. By route of administration the market is segmented as oral, parenteral, and topical and by distribution channel as hospital pharmacies, retail pharmacies, and online pharmacies.
By route of administration, oral treatment is expected to dominate the psoriatic arthritis market. The Food and Drug Administration (FDA) has approved Celgene Corporation's apremilast (Otezla), the first selective inhibitor of phosphodiesterase 4 (PDE4) prescribed for adults with moderate to severe plaque psoriasis, in March 2014. Otezla shows great improvement in the signs and symptoms of psoriatic arthritis. Otezla also offers patients and physicians a new psoriatic arthritis treatment option which increases the adoption of oral treatment.
Geographically, the global Psoriatic Arthritis Therapeutics market is divided into North America, Europe, South America, Asia-Pacific and the Middle East and Africa.
North America is expected to account for the highest share of the global market by 2026. High prevalence of psoriatic arthritis, increase in adoption of biologic drugs for the treatment of moderate to severe psoriatic arthritis and anticipated new product approvals are likely to fuel the psoriatic arthritis therapeutics market in North America. According to the Centre for Disease Control and Prevention (CDC), in 2017 around 1% of the total population of North America was suffering from psoriatic arthritis. In the US, psoriatic arthritis occurs in about 2% of the population and equally among both the sexes.
According to National Psoriasis Foundation, there are about 10 genes that seem to have an important role in Caucasian individuals in terms of predisposing them to psoriatic arthritis, but those same 10 genes did not appear to have any sort of effect in the Asian population, hence psoriatic arthritis is about five times more common in people of European descent than in people of Asian descent.
Some of the major key players in the market are AbbVie, Inc., Janssen Biotech, Inc., Novartis AG, Amgen, Inc., Celgene Corporation, Pfizer, Inc., Eli Lilly and Company, UCB, Inc., Biogen Inc., and Bristol-Myers and Squibb Company. Few of the recent key developments of the major companies include -
Global Psoriatic Arthritis Therapeutics Market Methodology and Scope